Abstract

The Program in Hematologic Diseases is structured around the Utah Blood and Marrow Transplant Program. The Program is supported by several state-of-the-art clinical laboratories and extensive clinical programs at the University Hospital, the Salt Lake Veterans Affairs Medical Center, the Primary Children's Medical Center, and the LDS Hospital. The Utah BMT Program in Hematologic Diseases has three specific aims. First, to improve the stem cell product used in reconstituting hematopoiesis following myeoablative procedures. Second, to expand the stem cell-marrow donor pool by optimizing recruitment strategies. Third, to define the role of stem cell-marrow transplantation in the treatment of relapsed acute lymphoblastic leukemia neuroblastoma, breast cancer, and acute myeloblastic leukemia relapsing after first allogeneic transplants. The laboratory research component of the program is focused on the biology of the hematopoietic stem cells and the molecular mechanisms regulating hematopoietic stem cell differentiation. The clinical research programs exploit the institution's experience in population genetics, the use of biologic response-modifying agents, molecular diagnostics, and the treatment of hematologic malignancies in children and adults.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA042014-14S1
Application #
6503934
Study Section
Project Start
2001-09-27
Project End
2002-04-30
Budget Start
Budget End
Support Year
14
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
University of Utah
Department
Type
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112

  Publications

Vahrenkamp, Jeffery M; Yang, Chieh-Hsiang; Rodriguez, Adriana C et al. (2018) Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor ? In Endometrial Cancer. Cell Rep 22:2995-3005
Gupta, Sumati; Albertson, Daniel; Gaston, David et al. (2018) Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clin Genitourin Cancer 16:e373-e382
Yazdimamaghani, Mostafa; Moos, Philip J; Ghandehari, Hamidreza (2018) Global gene expression analysis of macrophage response induced by nonporous and porous silica nanoparticles. Nanomedicine 14:533-545
Petersen, Jenna; Koptiuch, Cathryn; Wu, Yelena P et al. (2018) Patterns of family communication and preferred resources for sharing information among families with a Lynch syndrome diagnosis. Patient Educ Couns 101:2011-2017
Flack, Caralyn E; Parkinson, John S (2018) A zipped-helix cap potentiates HAMP domain control of chemoreceptor signaling. Proc Natl Acad Sci U S A 115:E3519-E3528
Al-Agha, Abdulmoein Eid; Ahmed, Ihab Abdulhamed; Nuebel, Esther et al. (2018) Primary Ovarian Insufficiency and Azoospermia in Carriers of a Homozygous PSMC3IP Stop Gain Mutation. J Clin Endocrinol Metab 103:555-563
Blackburn, Brenna E; Ganz, Patricia A; Rowe, Kerry et al. (2018) Reproductive and gynecological complication risks among thyroid cancer survivors. J Cancer Surviv 12:702-711
Wu, Yelena P; Aspinwall, Lisa G; Nagelhout, Elizabeth et al. (2018) Development of an Educational Program Integrating Concepts of Genetic Risk and Preventive Strategies for Children with a Family History of Melanoma. J Cancer Educ 33:774-781
Pishas, Kathleen I; Drenberg, Christina D; Taslim, Cenny et al. (2018) Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Mol Cancer Ther 17:1902-1916
Spiker, William Ryan; Brodke, Darrel S; Goz, Vadim et al. (2018) Evidence of an Inherited Predisposition for Spinal Cord Tumors. Global Spine J 8:340-344

Showing the most recent 10 out of 1193 publications